The Latest Breaking News from RBC

He was the biggest surprise on the list of names released for LIV Golf’s inaugural event.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) was slapped with a third FDA rejection for YCANTH (VP-102) as general contract manufacturing organization challenges continue to plague the approval. RBC Capital Markets has downgraded the stock to Sector Perform from Outperform and lowered the price target from $16 to $4. The analysts note that the issues fall outside of…

RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet.

Cigna Corp (NYSE:CI) posted 1Q22 adjusted EPS well above expectations on enterprise-wide growth, with a particularly solid performance in specialty pharmacy and better than expected MCR on lower testing and treatment costs.  The company raised FY22 guidance on 1Q outperformance. The analysts raised the price target to $272 from $235, with a Sector Perform rating. …

RBC Capital Markets believe that the market has been assigning little-to-no value to Tabula Rasa HealthCare Inc's (NASDAQ: TRHC) MedWise, which has been burning cash and clouding, a strong core PACE business. 

RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter. The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look,…

Even though the momentum of Palantir Technologies (PLTR) stock has been to the downside, contrarian tech investors should seize the opportunity to grab some shares.

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in the space could drive appreciation.